PerkinElmer to acquire RHS

PerkinElmer to acquire RHS

Adelaide-based single cell genomics company, RHS Limited, has entered into an agreement for PerkinElmer to acquire all issued share capital in RHS for 28 cents per share.

The deal, unanimously recommended by the board of RHS, will see a 100% premium paid for shares on the last listed share price for RHS, recorded on 23 February 2018.

RHS shareholders will vote on the deal at a meeting in May 2018.

RHS CEO Dr Michelle Fraser stated “The offer from PerkinElmer reinforces the considerable expertise that the RHS team have integrated into each of our products. Bringing RHS and PerkinElmer together provides an opportunity for our products to reach the clinical and applied research markets through a large and highly experienced global team.”

Read the ASX release here.

Back to News

TechInSA works closely with the hi-tech industry to bring innovative South Australian products and technologies to global markets.
TechInSA @TechInSA5
RT @StateDevSA: South Australia is buzzing with innovative #STEM research—this is your opportunity to showcase it! Nominations are now open…
TechInSA @TechInSA5
Exciting news for TGR Biosciences with SYGNIS AG intending to raise capital to acquire the…
TechInSA @TechInSA5
Great news for #Adelaide which is the first gigabit city outside the US to be part of the @US_Ignite program!…
Thank you! Your subscription has been confirmed. You'll hear from us soon.
Sign up to our eNewsletter
Subscribe to our e-Newsletter today to stay up-to-date on the latest hi-tech sector news.